# The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

> **NCT02449278** · PHASE3 · UNKNOWN · sponsor: **Wuhan University** · enrollment: 120 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **RADIATION:** Consolidation involved-site radiotherapy (ISRT)
- **RADIATION:** Consolidation involved-field radiotherapy (IFRT)
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin
- **DRUG:** vincristine
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT02449278
- **Lead sponsor:** Wuhan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2019-10
- **Final completion:** 2025-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2015-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02449278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02449278, "The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02449278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*